Complete Filing Data
Galmed Pharmaceuticals Ltd. reported Stockholders Equity of $15.78 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Galmed Pharmaceuticals Ltd. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$10.3M | -$7.5M | -$6.9M | -$17.9M | -$32.5M | -$28.8M | -$20.5M | -$9.9M | -$12.3M | -$17.0M | -$10.6M | -$9.1M | -$17.5M | -$3.1M |
| Revenue * | $0.00 | $0.00 | $2.0M | $1.1M | $467.0K | $0.00 | $0.00 | |||||||
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | $113.0K | $38.0K | $291.0K | -$574.0K | -$443.0K | $237.0K | $46.0K | -$4.0K | $78.0K | $121.0K | -$210.0K | $4.0K | $0.00 | $0.00 |
| Research And Development Expense | $4.9M | $3.0M | $3.6M | $13.0M | $27.2M | $26.1M | $18.2M | $8.3M | $9.7M | $14.3M | $7.6M | $6.7M | $7.2M | $2.4M |
| General And Administrative Expense | $3.6M | $3.3M | $3.9M | $4.7M | $5.7M | $4.1M | $4.2M | $4.4M | $3.8M | $3.1M | $3.2M | $2.5M | $7.4M | $694.0K |
| Operating Expenses | $8.5M | $6.3M | $7.5M | $17.7M | $32.9M | $30.2M | $22.4M | $10.7M | $12.4M | $16.9M | $10.9M | $9.1M | $14.6M | $3.1M |
| Other Nonoperating Income Expense | $741.0K | $516.0K | $580.0K | -$215.0K | $414.0K | $1.4M | $1.9M | $934.0K | $65.0K | $35.0K | ||||
| Comprehensive Income Net Of Tax | -$28.5M | -$20.4M | -$9.9M | -$12.2M | -$16.8M | -$10.8M | -$9.1M | -$17.5M | -$3.1M | |||||
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -$10.2M | -$7.5M | -$6.6M | -$18.4M | -$32.9M | -$28.5M | -$20.4M | |||||||
| Income Loss From Continuing Operations Per Basic And Diluted Share | $1.35 | $0.97 | $0.54 | $0.98 | $1.49 | $0.96 | $0.88 | $3.45 | $0.63 | |||||
| Income Tax Expense Benefit | $0.00 | $0.00 | $75.0K | $0.00 | $106.0K | $0.00 | $1.0K | $1.0K | $6.0K | |||||
| Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments | -$28.8M | -$20.5M | -$9.8M | -$12.3M | -$16.8M | -$10.6M | -$9.1M | -$17.5M | -$3.1M | |||||
| Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments | $527.0K | $9.0K | -$12.0K | -$143.0K | -$231.0K | -$50.0K | $0.00 | $0.00 | ||||||
| Nonoperating Income Expense | $65.0K | $35.0K | $253.0K | $40.0K | -$2.9M | -$6.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $15.8M | $16.3M | $13.9M | $13.4M | $30.5M | $44.2M | $69.9M | $87.9M | $15.8M | $11.1M | $21.5M | $31.4M | -$2.0M | -$2.0M | -$2.7M |
| Cash And Cash Equivalents At Carrying Value | $4.0M | $4.7M | $2.9M | $2.0M | $2.9M | $6.9M | $15.9M | $24.2M | $13.0M | $3.1M | $4.2M | $23.7M | $137.0K | $718.0K | $146.0K |
| Amortization Of Debt Discount Premium | $15.0K | -$17.0K | $19.0K | -$2.0K | $121.0K | $90.0K | -$105.0K | -$144.0K | $21.0K | $44.0K | $92.0K | $0.00 | $0.00 | ||
| Retained Earnings Accumulated Deficit | -$210.8M | -$200.5M | -$193.0M | -$186.0M | -$168.2M | -$135.7M | -$106.9M | -$86.5M | -$76.6M | -$64.3M | -$47.4M | -$36.7M | -$27.6M | ||
| Liabilities Current | $2.8M | $2.2M | $2.8M | $3.1M | $5.9M | $8.0M | $6.9M | $2.7M | $3.8M | $4.6M | $2.5M | $1.1M | $1.7M | ||
| Liabilities And Stockholders Equity | $18.6M | $18.5M | $16.6M | $16.6M | $36.6M | $52.4M | $77.1M | $90.6M | $19.6M | $16.5M | $24.3M | $32.9M | $166.0K | ||
| Common Stock Value | $3.4M | $742.0K | $209.0K | $70.0K | $70.0K | $58.0K | $58.0K | $58.0K | $40.0K | $34.0K | $32.0K | $32.0K | $10.0K | ||
| Assets Current | $18.6M | $16.1M | $13.2M | $14.7M | $36.1M | $51.8M | $76.4M | $90.4M | $19.2M | $15.7M | $23.4M | $32.2M | $153.0K | ||
| Assets | $18.6M | $18.5M | $16.6M | $16.6M | $36.6M | $52.4M | $77.1M | $90.6M | $19.6M | $16.5M | $24.3M | $32.9M | $166.0K | ||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$303.0K | -$416.0K | -$454.0K | -$745.0K | -$171.0K | $272.0K | $35.0K | -$11.0K | -$7.0K | -$85.0K | -$206.0K | $4.0K | $0.00 | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $4.1M | $4.8M | $3.0M | $2.1M | $3.0M | $7.1M | $16.0M | $24.2M | |||||||
| Debt Securities Available For Sale Unrealized Gain Loss | $113.0K | $38.0K | $291.0K | -$574.0K | -$443.0K | $237.0K | $46.0K | ||||||||
| Property Plant And Equipment Net | $83.0K | $114.0K | $145.0K | $176.0K | $171.0K | $194.0K | $491.0K | $718.0K | $883.0K | $774.0K | $13.0K | ||||
| Assets Noncurrent | $2.4M | $3.4M | $1.8M | $551.0K | $570.0K | $709.0K | $194.0K | ||||||||
| Restricted Cash Current | $124.0K | $121.0K | $117.0K | $114.0K | $114.0K | $113.0K | $112.0K | $0.00 | |||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$664.0K | $1.8M | $848.0K | -$868.0K | -$4.1M | -$9.0M | -$8.1M | ||||||||
| Marketable Securities | $40.1M | $31.6M | $60.0M | $6.0M | $12.4M | $18.8M | $2.3M | $0.00 | |||||||
| Accounts Payable Trade Current | $7.0M | $6.0M | $1.8M | $2.3M | $3.1M | $2.3M | $875.0K | $1.4M | |||||||
| Accounts Payable Other Current | $966.0K | $935.0K | $892.0K | $1.0M | $363.0K | $282.0K | $243.0K | $334.0K | |||||||
| Accounts And Other Receivables Net Current | $812.0K | $827.0K | $218.0K | $155.0K | $284.0K | $379.0K | $165.0K | $16.0K | |||||||
| Cash And Cash Equivalents Period Increase Decrease | $11.1M | $9.9M | -$1.1M | -$19.6M | $23.6M | -$581.0K | $572.0K | ||||||||
| Other Receivables Net Current | $347.0K | $672.0K | $480.0K | $825.0K | $1.1M | $812.0K | |||||||||
| Other Loans Payable Current | $842.0K | $865.0K | $871.0K | $534.0K | $1.0M | $966.0K | |||||||||
| Operating Lease Right Of Use Asset | $42.0K | $223.0K | $406.0K | $394.0K | $538.0K | $0.00 | |||||||||
| Marketable Securities Current | $7.0M | $7.2M | $7.5M | $11.8M | $31.9M | $40.1M | |||||||||
| Accounts Payable Current | $2.0M | $1.3M | $1.9M | $2.6M | $4.9M | $7.0M | |||||||||
| Liabilities Noncurrent | $44.0K | $229.0K | $216.0K | $352.0K | $0.00 | ||||||||||
| Operating Lease Liability Noncurrent | $44.0K | $229.0K | $216.0K | $352.0K | $0.00 | ||||||||||
| Deposits Assets Current | $7.1M | $3.5M | $2.3M | $3.8M | |||||||||||
| Short Term Investments | $3.8M | $27.9M | $6.1M | $0.00 | $0.00 | $6.0M | $0.00 |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financing Cash Flow * | $9.0M | $8.8M | $6.2M | $70.0K | $17.4M | $768.0K | $143.0K | $80.2M | $15.5M | $4.7M | $0.00 | $41.9M | $1.9M | $3.7M |
| Investing Cash Flow * | -$3.4M | -$1.1M | $800.0K | $17.6M | $11.5M | $16.5M | $6.7M | -$60.0M | $6.4M | $6.3M | -$11.1M | -$9.0M | $3.0K | -$32.0K |
| Operating Cash Flow * | -$6.3M | -$5.9M | -$6.1M | -$18.5M | -$32.9M | -$26.3M | -$14.9M | -$9.0M | -$12.1M | -$12.1M | -$8.5M | -$9.2M | -$2.5M | -$3.1M |
| Share Based Compensation | $546.0K | $531.0K | $892.0K | $1.3M | $1.9M | $2.1M | $2.2M | $1.8M | $1.4M | $1.6M | $970.0K | $601.0K | $10.9M | $208.0K |
| Increase Decrease In Other Accounts Payable | -$23.0K | $35.0K | $468.0K | -$440.0K | $38.0K | $8.0K | -$144.0K | -$142.0K | $671.0K | $81.0K | $39.0K | -$91.0K | $228.0K | -$103.0K |
| Increase Decrease In Accounts Payable Trade | $695.0K | -$571.0K | -$681.0K | -$2.3M | -$2.2M | $1.0M | $4.2M | -$462.0K | -$846.0K | $863.0K | $1.4M | -$480.0K | $954.0K | -$89.0K |
| Increase Decrease In Accounts And Other Receivables | -$240.0K | $192.0K | -$345.0K | -$300.0K | $313.0K | -$15.0K | $609.0K | $63.0K | -$129.0K | -$95.0K | $214.0K | $149.0K | $2.0K | $11.0K |
| Payments To Acquire Property Plant And Equipment | $4.0K | $11.0K | $44.0K | $12.0K | $90.0K | $12.0K | $17.0K | $159.0K | $770.0K | $13.0K | $32.0K | |||
| Depreciation Depletion And Amortization | $42.0K | $39.0K | $35.0K | $387.0K | $239.0K | $169.0K | $50.0K | $9.0K | $4.0K | $5.0K | ||||
| Proceeds From Issuance Of Common Stock | $7.7M | $4.4M | $4.4M | $9.2M | $707.0K | $15.0M | $4.5M | $0.00 | $2.0M | $120.0K | $0.00 | |||
| Payments For Proceeds From Short Term Investments | -$3.8M | -$24.4M | $21.8M | $6.1M | $0.00 | $0.00 | -$6.0M | $6.0M | $0.00 | |||||
| Proceeds From Sale And Maturity Of Available For Sale Securities | $47.2M | $101.1M | $38.4M | $10.3M | $14.0M | $9.6M | $0.00 | $0.00 | ||||||
| Proceeds From Interest Received | $1.2M | $2.0M | $865.0K | $202.0K | $382.0K | $473.0K | $0.00 | $0.00 | ||||||
| Proceeds From Stock Options Exercised | $61.0K | $143.0K | $1.0M | $530.0K | $255.0K | $0.00 | $0.00 | |||||||
| Increase Decrease In Due To Related Parties | $0.00 | $0.00 | -$267.0K | $90.0K | -$223.0K | -$28.0K | $38.0K | $60.0K | ||||||
| Payments To Acquire Available For Sale Securities | $92.3M | $3.9M | $7.6M | $26.5M | $2.2M | $0.00 | $0.00 | |||||||
| Proceeds From Sale Of Available For Sale Securities Debt | $1.6M | $5.5M | $8.6M | $21.4M | $21.2M | $47.2M | $101.1M | |||||||
| Proceeds From Sale Of Property Plant And Equipment | $0.00 | $0.00 | $13.0K | $0.00 | $0.00 | $16.0K | $0.00 | |||||||
| Proceeds From Issuance Initial Public Offering | $70.0K | $8.1M | $0.00 | $0.00 | $39.9M | $0.00 | $0.00 | |||||||
| Payments For Investment In Available For Sale Securities | $5.1M | $4.1M | $2.4M | $13.6M | $55.0M | $72.6M | ||||||||
| Increase Decrease In Deferred Revenue | -$538.0K | -$1.1M | $1.6M | $0.00 | $0.00 |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Shares Authorized | 900.0M | 900.0M | 50.0M | 20.0M | 50.0M | 50.0M | 50.0M | 50.0M | 50.0M | 50.0M | 50.0M | 50.0M | 50.0K | |
| Weighted Average Number Of Share Outstanding Basic And Diluted | 21.3M | 21.1M | 18.1M | 12.5M | 11.4M | 11.1M | 10.3M | 5.1M | 5.0M | |||||
| Common Stock Shares Outstanding | 6.6M | 1.7M | 573.7K | 1.7M | 25.1M | 21.3M | 21.1M | 21.0M | 14.4M | 12.1M | 11.1M | 11.1M | 9.7K | |
| Common Stock Par Or Stated Value Per Share | $1.80 | $1.80 | $1.80 | $0.15 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $1.00 | |
| Common Stock Shares Issued | 6.6M | 1.7M | 573.7K | 1.7M | 25.1M | 21.3M | 21.1M | 21.0M | 14.4M | 12.1M | 11.1M | 11.1M | 9.7K | |
| Weighted Average Number Of Diluted Shares Outstanding | 4.3M | 930.8K | 230.8K | 139.7K | 1.6M | 21.3M | 21.1M | |||||||
| Earnings Per Share Basic | $2.39 | $8.08 | $30.00 | $127.80 | $19.80 | $1.35 | $0.97 | |||||||
| Weighted Average Number Of Shares Outstanding Basic | 4.3M | 930.8K | 230.8K | 139.7K | 1.6M | |||||||||
| Earnings Per Share Diluted | $2.39 | $8.08 | $30.00 | $127.80 | $19.80 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options | $546.0K | $531.0K | $892.0K | $1.3M | $1.9M | $2.1M | $2.2M | $1.8M | $1.4M | $1.6M | $970.0K | $601.0K | $10.9M | $208.0K |
| Additional Paid In Capital | $223.5M | $216.5M | $207.1M | $200.1M | $198.8M | $179.5M | $176.7M | $174.3M | $92.4M | $75.4M | $69.1M | $68.1M | $25.7M | |
| Interest Paid Net | $914.0K | $503.0K | $376.0K | $297.0K | $562.0K | $1.2M | $2.0M | |||||||
| Stock Issued During Period Value New Issues | $7.7M | $70.0K | $9.2M | $707.0K | $79.1M | $15.0M | $4.5M | $2.0M | $120.0K | |||||
| Stock Issued During Period Value Restricted Stock Award Gross | $61.0K | $143.0K | $1.0M | $530.0K |
Most recent annual filing with the SEC: March 31, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.